The Vaginal Microbiome and Implantation: What Every Fertility Practitioner Needs to Know

There is a good chance your clients have already googled a vaginal microbiome test. They may well have even ordered it online, received a report full of percentages and Latin names, and arrived at your consultation with a printout and a look of confusion. They know something about Lactobacillus. They know one result is better than another. They do not know what any of it means for their chances of conceiving, or what they should actually do about it.

This is one of the fastest-growing areas in reproductive medicine and was covered in the ESHRE webinar session for the first time in 2024.  The research is compelling, the clinical implications are significant, and almost no nutritional therapy training programme covers it at any meaningful depth.

If you are working with fertility clients and you do not yet understand the vaginal microbiome, this is the area where your knowledge gap is most likely to cost a client her next cycle.

Why the vaginal microbiome is unlike every other microbiome you have studied

Everything you learned about gut microbiome health applies here in reverse.

In the gut, diversity is the goal. A rich, varied community of bacterial species is associated with good health outcomes. The more species present in appropriate balance, the better.

In the vagina, the opposite is true. In contrast to the gut, where a diverse community is considered healthy, in the vagina a low-diversity community dominated by Lactobacillus is a marker of health. A healthy vaginal microbiome is a simple one. Dominated by a single species. Low in diversity. Highly acidic. Inhospitable to pathogenic organisms. 

The moment you introduce diversity into the vaginal environment, the moment other bacterial species begin to establish themselves and compete with Lactobacillus dominance  you are looking at a less protective environment. One that is associated with inflammation, altered pH, and, critically, compromised implantation.

Understanding this distinction is the starting point for everything else.

Not all Lactobacillus species are equal

Here is where most practitioners who have a basic awareness of the vaginal microbiome get stuck. They know that Lactobacillus dominance is good. What they often do not know is that different Lactobacillus species produce very different outcomes, and the distinction matters enormously in a fertility context.

There are four main vaginal Lactobacillus species: L. crispatus, L. iners, L. gasseri, and L. jensenii. Of these, L. crispatus is the gold standard. It produces the most lactic acid, maintains the lowest pH, is the most metabolically stable, and is the most strongly associated with reproductive health outcomes.

L. iners is the species that confuses practitioners most. A vaginal microbiome can appear Lactobacillus-dominant on a test result and still be suboptimal if L. iners is the dominant species rather than L. crispatus. L. iners produces less lactic acid, has a more unstable ecological niche, and is more readily displaced by dysbiotic species. It is often described as a transitional species , more protective than a dysbiotic environment, but significantly less protective than L. crispatus dominance.

When you are looking at a client's vaginal microbiome test result, the critical question is not just whether Lactobacillus is present. It is which Lactobacillus is dominant, and in what proportion.

What the evidence actually shows about implantation

The research linking vaginal and endometrial microbiome composition to IVF outcomes has been building for several years and is now substantial enough to be clinically actionable.

A vaginal microbiome dominated by L. crispatus has been significantly associated with increased rates of embryo implantation and live births after IVF. Conversely, an imbalanced vaginal microbiome with low levels of Lactobacillus and high levels of unfriendly bacteria can negatively impact fertility and IVF success. 

The scale of the effect is striking. Bioinformatic analysis showed that a high relative abundance of Lactobacillus crispatus increased the likelihood of pregnancy approximately sixfold. Women with an unfavourable microbiome had more miscarriages than women with a favourable microbiome. 

Sixfold. Not a marginal benefit. A sixfold increase in the likelihood of achieving pregnancy.

Research confirms the beneficial role of vaginal lactobacilli, especially Lactobacillus crispatus, in the probability of achieving clinical pregnancy and live birth following IVF embryo transfer. These findings may help clinicians in their attempts to optimise the conditions for embryo transfer by microbiota screening or modulation and timing the transfer when the microbiota is the most favourable. 

Women with a live birth following failed IVF cycles had significantly higher Lactobacillus crispatus relative abundance compared to those without, and a smaller proportion of them had very low L. crispatus levels. 

This is not fringe research. This is published in Nature Medicine, PMC, and Human Reproduction. It is being used by forward-thinking IVF clinics in the US and Europe to guide embryo transfer timing. And yet most nutritional therapy practitioners in the UK have no framework for it whatsoever.

How PMOS and insulin resistance disrupt the vaginal microbiome

This is where the clinical picture for your PMOS clients becomes particularly important, and where the connection between the metabolic and the reproductive is most clearly visible.

Hormonal imbalance and insulin resistance are factors that not only affect ovulation but also change the gut and vaginal microbiota. The mechanism runs in several directions simultaneously. 

Elevated blood glucose from insulin resistance directly feeds dysbiotic bacteria and yeast in the vaginal environment. Gardnerella vaginalis, the primary driver of bacterial vaginosis, thrives in a glucose-rich, less acidic environment. Candida species similarly exploit the elevated sugar availability that insulin resistance creates. The vaginal environment that results is warmer, higher in pH, and more hospitable to pathogenic colonisation, and less hospitable to the L. crispatus dominance you need.

In IVF patients with diverse or pathogen-rich flora, especially those dominated by L. iners, Gardnerella, or Pseudomonas, implantation and live birth rates are significantly worse than in those with Lactobacillus-dominant vaginal or endometrial microbiota. 

The androgenic environment of PMOS adds another layer. Elevated testosterone and DHEAS alter the vaginal epithelial cell turnover and glycogen availability, which is the primary food source for Lactobacillus. When androgens are elevated and the vaginal epithelium is not producing adequate glycogen, Lactobacillus species are starved of their preferred substrate and less able to maintain dominance.

Then there is the systemic inflammatory picture. Gut dysbiosis in PCOS drives up serum insulin levels, disrupts insulin receptor function, increases the level of androgens, and interferes with normal follicle development. That same systemic inflammatory signalling reaches the vaginal environment and disrupts the immune tolerance that L. crispatus dominance maintains. 

Your PMOS clients are therefore at significantly elevated risk of vaginal dysbiosis, often without any symptoms whatsoever. The most clinically concerning forms of dysbiosis are entirely asymptomatic. No discharge, no odour, no discomfort. Just a quietly disrupted microbiome that is silently compromising the implantation environment.

You have done the test. But can you interpret it for fertility?

Here is the reality that practitioners often discover only after they have started ordering vaginal microbiome tests for clients: getting the test result is the easy part. Knowing what to do with it is where clinical training is genuinely required.

A vaginal microbiome report will typically show you the bacterial species present, their relative abundance as percentages, and a community state type classification. What it will not tell you is how those findings specifically relate to your client's fertility history, her PMOS picture, her upcoming FET cycle, whether the oestradiol she is about to take to thicken her lining is likely to feed the BV pattern you are looking at, or what the realistic timeline is for shifting the microbiome before her embryo transfer window.

That interpretation requires clinical knowledge that sits at the intersection of reproductive medicine, microbiology, and nutritional therapy. It is not intuitive. And it is not something you can piece together from the report itself.

Practitioners who have done the vaginal microbiome test themselves, or who have ordered it for clients without the clinical framework to interpret it, often describe the same experience: the result raises more questions than it answers. What does this percentage of L. iners mean practically? Should I be concerned about this level of Gardnerella if there are no symptoms? How does the oestrogen protocol from her clinic change the picture? What is the difference between treating this with oral probiotics versus vaginal suppositories versus a full reset protocol?

These are the questions that require training to answer.

What practitioners can do nutritionally

The vaginal microbiome is responsive to nutritional intervention, and there is meaningful clinical work you can do both to support a healthy microbiome and to address dysbiosis when it is present.

The foundation is addressing the systemic drivers. For PMOS clients, this means optimising blood sugar through the dietary and supplement protocol that targets insulin resistance, because reducing the glucose availability that feeds dysbiotic organisms is a primary intervention. Inositol, ALA, berberine where appropriate, magnesium, a low glycaemic dietary approach, and adequate protein at every meal all contribute to the metabolic environment that supports Lactobacillus dominance.